2026年11月4日星期三
M
Weltübersicht
Globale Kurznachrichten
Mitsui Chemicals to buy Japan chip material maker JSR for over $8.2bn— 日经 Nikkei AsiaPetrovietnam CEO sees a future of nuclear and wind power— 日经 Nikkei AsiaTaiwan airlines continue flights over Russia, rattling Europeans— 日经 Nikkei AsiaDebt costs curb growth for developing nations, Rockefeller official says— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaMitsui Chemicals to buy Japan chip material maker JSR for over $8.2bn— 日经 Nikkei AsiaPetrovietnam CEO sees a future of nuclear and wind power— 日经 Nikkei AsiaTaiwan airlines continue flights over Russia, rattling Europeans— 日经 Nikkei AsiaDebt costs curb growth for developing nations, Rockefeller official says— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei Asia

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial

Quelle Nature 生命科学Vor 1 Tagen
Inhaltszusammenfassung

Diese Website bietet nur Titel- und Zusammenfassungsindexe. Der vollständige Inhalt und das Urheberrecht liegen beim ursprünglichen Herausgeber. Bitte klicken Sie auf den Original-Link, um ihn zu lesen.

Zum Originaltext
Zugehöriger Kanal
Wissenschaft
Zugehörige Region
Globale Perspektive
Originalsprache
English
Eintragsnummer
science-f81c0280

Comments 0 comments

No comments yet. Be the first.

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial · Weltübersicht